Tamtam Try Tamtam free
St. Jude Children's Research Hospital logo

St. Jude Children's Research Hospital account plan

Pediatric cancer research and treatment

At a glance

St. Jude is a Memphis non-profit research hospital for sick children, seeing over 9,300 patients a year; FY2025 expenses were $1.9 billion.

St. Jude Children's Research Hospital, Inc. is a not-for-profit research, treatment and education center in Memphis, Tennessee, whose mission is to find the causes of catastrophic childhood illnesses, improve treatments and find cures; no family ever pays the hospital for its child's care. It sees more than 9,300 patients a year, accounting for about 75,000 hospital visits, mostly outpatient within research programs. In the year ended June 30, 2025 total expenses were $1,897,572K, against its own revenues, gains and other support of $341,483K; the gap is funded by its fundraising affiliate ALSAC, which provided net support of $1,878,045K. Total net assets reached $12,561,643K, most of it the hospital's interest in ALSAC's net assets.

Business units

Strategic priorities

New therapeutic modalities
Incoming CEO Charles Roberts sees a convergence of technologies, including AI to design small molecules, PROTACs and glues, RNA therapeutics, antibody drug conjugates and CAR-T cells, that can treat childhood cancers more effectively with less toxicity.
Diseases beyond cancer
The same modalities could make inherited genetic diseases of children treatable, widening St. Jude's scope to more catastrophic childhood diseases.
Global expansion
St. Jude plans to treat more children around the world; ALSAC's six-year $12.9 billion plan aims to provide pediatric cancer cures and treatments globally.
Clinical outpatient facilities
A $1 billion outpatient building programme, with $639.5 million in construction in progress at June 30, 2025, is expected substantially complete in calendar 2026.
Free care for families
Treatment stays free for patients and families, funded by ALSAC philanthropy.

Investments and deals

Campus construction
Capital expenditures rose to $452,643K in FY2025 from $380,188K, and construction in progress grew to $774,406K, mainly for the clinical outpatient facilities.
IT and cloud
Computer hardware and software assets grew to $267,965K from $243,416K, with capitalized cloud computing implementation costs.
Global access to medicines
Total estimated contributions of $107 million for fiscal 2024 through 2027 under a memorandum with a procurement agency, of which $32 million had been contributed by June 30, 2025.

Challenges and risks

Federal research funding
Federal awards expended were $137,833,439 in FY2025, almost all from the Department of Health and Human Services, and incoming CEO Roberts names federal cuts to scientific research funding as a constraint.
Limited pharma investment
Pharmaceutical companies invest less in childhood cancers than in adult cancers, which St. Jude cannot fully replace.
Dependence on ALSAC
The hospital's own revenues cover a minority of costs, so it depends on ALSAC fundraising and on ALSAC's largely illiquid investment returns.
Rising costs
Total expenses rose to $1,897,572K from $1,772,679K, with salaries and benefits at $1,041,996K.
Reimbursement complexity
The receivables mix shifted toward Medicaid (41% at June 30, 2025 from 29%), and reimbursement laws are described as extremely complex and subject to interpretation.

What leadership says

“I think we are at the dawn of a new era”

Charles W. M. Roberts, President and CEO-designate · AP interview published by Fortune, August 19, 2026

“We can't go all the way and completely replace what pharma does”

Charles W. M. Roberts, President and CEO-designate · AP interview published by Fortune, August 19, 2026

“I think this is not rocket science. This is much harder.”

Charles W.M. Roberts, EVP and Director of the Comprehensive Cancer Center · STAT conversation, May 18, 2026

“My role is to make sure that ALSAC is able to deliver on its promises to St. Jude so that St. Jude can continue to dream big”

Ike Anand, President and CEO, ALSAC · AP interview, July 8, 2025

Where a supplier can help

Research technology and AI drug design
Tied to the new therapeutic modalities priority: AI and computational chemistry tools, lab automation and data platforms for small-molecule, RNA and cell therapy research.
Hospital fit-out and operations
Tied to the $1 billion clinical outpatient facilities programme: medical equipment, facility systems and moving-in services as the buildings complete in 2026.
Grant and research administration
Tied to the federal research funding challenge: grant management and compliance tools that protect and diversify research funding.
Global programme logistics
Tied to the global expansion priority: supply chain, procurement and digital health partners for treating children outside the U.S.
Fundraising data and donor trust
Tied to the dependence on ALSAC: donor analytics and privacy-safe AI tools, in line with ALSAC's use of aggregated data for donor communications.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like St. Jude Children's Research Hospital?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about St. Jude Children's Research Hospital

What does St. Jude Children's Research Hospital do?

St. Jude is a not-for-profit research, treatment and education center in Memphis that seeks causes and cures for catastrophic childhood illnesses and treats more than 9,300 patients a year free of charge to families.

How is St. Jude funded?

Its own revenues of $341,483K in FY2025 covered a minority of its $1,897,572K of expenses; ALSAC, its fundraising affiliate, provided net support of $1,878,045K.

Who leads St. Jude Children's Research Hospital?

Dr. James R. Downing led St. Jude for 12 years; Dr. Charles W. M. Roberts, director of the Comprehensive Cancer Center, was named president and CEO starting Jan. 1. Judy A. Habib chairs the Board of Governors.

What is St. Jude's strategy?

Use a convergence of new therapeutic technologies to cure more childhood cancers with less toxicity, extend to other catastrophic childhood diseases, and expand care to more children around the world.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)